Related Experiment Videos
Simultaneous chemoradiation in advanced non-small cell lung cancer
1Department of Radiation Oncology, Beth Israel Medical Center, New York, New York 10003.
Seminars in Surgical Oncology
|March 1, 1993
Summary
This study evaluated accelerated chemoradiation for advanced lung cancer, finding the regimen well-tolerated with promising 2-year survival rates comparable to existing treatments.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Advanced lung cancer presents significant treatment challenges.
- Optimizing local control and survival remains a critical objective in lung cancer therapy.
Purpose of the Study:
- To assess the safety and efficacy of a novel, accelerated chemoradiation regimen.
- To improve local control and survival outcomes in patients with advanced lung cancer (Stage IIIA/IIIB).
Main Methods:
- Forty-one patients with Stage IIIA/IIIB lung cancer received simultaneous chemoradiation.
- The regimen involved cisplatin, VP-16, and 5-Fluorouracil (5-FU) with accelerated, twice-daily radiation therapy over repeated cycles.
- Surgical resection was evaluated after the second cycle.
Main Results:
- The chemoradiation regimen demonstrated acceptable acute toxicity.
- One-year actuarial survival was 60.3%, and 2-year actuarial survival was 55.3%.
- Three treatment-related deaths occurred (congestive heart failure, sepsis, pulmonary embolism).
Conclusions:
- The accelerated chemoradiation regimen is well-tolerated in advanced lung cancer patients.
- The observed 2-year survival rates appear comparable to established treatment protocols.
- This approach warrants further investigation for improving outcomes in advanced lung cancer.